Allogene Therapeutics (ALLO) announced that it has entered into a non-exclusive licensing agreement with privately-held Arbor Biotechnologies to utilize the latter’s proprietary CRISPR gene-editing technology.Allogene intends to utilize Arbor’s CRISPR technology with its own proprietary platform to develop next-generation allogeneic CAR T (AlloCAR T) therapies targeting autoimmune diseases (AID).However, neither of the companies disclosed any specific financial terms or considerations pertaining to the abov ...

Exhibit 99.1 Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update • Cema-cel Pivotal ALPHA3 First Line (1L) Consolidation Trial in Large B-Cell Lymphoma (LBCL): Start-Up Activities Underway; Enrollment to Begin Mid-2024 • Cema-cel Phase 1 ALPHA2 Trial in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Enrolling Patients with Initial Data Projected YE 2024 • ALLO-329 in Autoimmune Disease (AID): Differentiated Next-Generation CD19 Dagger Program Design ...

Table of Contents | --- | --- | --- | |-------|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | _________________________________ Commission File Number | | | | Allogene Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) ____________________ ...

Allogene's AlloCAR T™ Autoimmune Disease Platform Leverages Arbor's CRISPR Gene-Editing TechnologyFirst Allogeneic CAR T Phase 1 Clinical Trial in Autoimmune Disease Expected to Initiate in Early 2025 SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, and Arbor Biotechnologies, Inc. ("Arbor" ...

Core Insights - Allogene Therapeutics, Inc. (ALLO) has reached a significant support level, indicating potential for investors from a technical perspective [1] - The recent breakout of ALLO's 50-day simple moving average above its 200-day moving average signifies a "golden cross," which is a bullish indicator [1][2] - ALLO's shares have increased by 31.9% over the past four weeks, suggesting positive momentum [2] Technical Analysis - A golden cross is formed when a short-term moving average crosses above a long-term moving average, typically the 50-day and 200-day, indicating a potential bullish breakout [1] - The successful golden cross event consists of three stages: a price bottom, the crossover of moving averages, and the maintenance of upward momentum [1] Earnings Outlook - ALLO is currently rated 3 (Hold) on the Zacks Rank, indicating potential for a breakout [2] - The positive earnings outlook for the current quarter is reinforced by one upward revision in earnings estimates and no downward revisions in the past two months [2] - The Zacks Consensus Estimate for ALLO has also increased, further solidifying the bullish case for the company [2]

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report fourth quarter and full year 2023 financial results and provide a business update on March 14, 2024, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/ ...

No Impact on Cash, Cash Equivalents and Marketable Investments, Cash Runway or Business OperationsCompany Targeting On or Before March 14, 2024 to File Amended Financial Statements and Report Fourth Quarter and Full Year 2023 Financial Results SOUTH SAN FRANCISCO, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced it ...

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conferences in January and February. B. Riley Oncology ConferenceThursday, January 18, 202412:30PM PT/3:30PM ET Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceWednesday, February ...

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conferences in January and February. B. Riley Oncology ConferenceThursday, January 18, 202412:30PM PT/3:30PM ET Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceWednesday, February ...

One stock that might be an intriguing choice for investors right now is Allogene Therapeutics, Inc. (ALLO) . This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably t ...